Edwin Paz

Edwin Paz is a notable inventor based in Durham, NC (US), recognized for his contributions to cancer therapy innovations. With a focus on therapeutic methods, he has developed significant patents that aim to improve treatment outcomes for patients.

Latest Patents

Edwin Paz holds 2 patents related to predictive markers for polyamine inhibitor cancer therapies. His inventions involve the identification and use of cancer marker surrogates for increased polyamine expression. These markers are crucial for identifying patients who may benefit from treatments involving polyamine synthesis inhibitors. Additionally, they serve to monitor therapeutic responses when such agents are utilized. Specifically, his research indicates that reduced levels of let-7 miRNA and elevated levels of LIN28 and HMGA2 proteins correlate with increased polyamine levels, which can predict the efficacy of cancer therapy using ornithine decarboxylase (ODC1) inhibitors like eflornithine (DFMO), especially when combined with NSAIDs such as sulindac.

Career Highlights

Edwin Paz is affiliated with the University of Arizona, where he continues to advance his research in cancer therapies. His work is characterized by a commitment to improving patient care through innovative therapeutic strategies.

Collaborations

He collaborates with esteemed colleagues, including Eugene W Gerner and Bonnie LaFleur, to further enhance the impact of his research in the field of cancer treatment.

Conclusion

Edwin Paz's contributions to cancer therapy through his innovative patents highlight his dedication to improving treatment methodologies. His work not only aids in patient identification for specific therapies but also enhances the monitoring of treatment responses, showcasing the importance of innovation in medical science.

Profile summary based on public USPTO records.